Intellectual PropertyThe filing of utility patents for pitolisant HD and GR extends intellectual property protection out to 2044, strengthening the company's competitive position.
Pipeline DevelopmentHarmony's expanding pipeline and fine-tuning of commercial assumptions for WAKIX reinforce confidence in the upcoming top-line readout from the Phase 3 RECONNECT trial in Fragile X syndrome.
Revenue GrowthHarmony is off to a strong start in 2025, reporting 1Q25 net product revenue of $184.7M, up 20% year-over-year, driven by continued commercial execution in narcolepsy.